Podcasts about america idsa

This episode features Prof. Cynthia L. Sears, MD from the Johns Hopkins University School of Medicine and the Bloomberg School of Public Health (USA), speaking about both biofilms and specific gut microorganisms that may contribute to colorectal cancer development. Initially, Prof. Sears became interested in enterotoxigenic Bacteroides fragilis in connection with colon cancer. Further investigation found complex biofilms with multiple bacteria fixed to the surface of the tumor. The biofilms were shown to be oncogenic, and they reassembled very quickly after antibiotic treatment. Interestingly, the biofilms were found to have C. difficile. A subset of the biofilms have a dominant amount of Fusobacterium, and the latest work shows that these bacteria are associated with advancing cancer, stage 2 or beyond. These bacteria and/or biofilms don't necessarily trigger the onset of mutations that lead to colon cancer, but they accelerate tumor growth. Over time, the gut microbiota may be perturbed in various ways (including by antibiotics), allowing the organisms to create a niche for themselves that ultimately harms the colonic epithelial cells. Prof. Sears is optimistic about prevention strategies for colorectal cancer, such as a tool that helps predict risk in younger populations. Targeted prebiotics, too, show promise for encouraging the growth of beneficial bacteria that prevent the oncogenic species from finding a niche. Episode abbreviations and links: 2014 review by Sears and Garrett on the role of microbes in colon cancer: Microbes, Microbiota, and Colon Cancer One of the landmark 2012 papers linking Fusobacterium nucleatum to colorectal cancer: Fusobacterium nucleatum infection is prevalent in human colorectal carcinoma Examination of biofilms on colon cancer polyps: Epidemiology of bacterial biofilms on polyps and normal tissues in a screening colonoscopy cohort Association of Fusobacterium with advancing (stage 2) colorectal cancer: Tumor-Associated Fusobacterium nucleatum and Aggressive Architectural Features in Stage II Colorectal Cancer Paper showing genotoxic microbes increasing colon tumor burden: Combining genotoxic gut bacterial strains increases tumor burden and accelerates onset in a germ-free mouse model of colon carcinogenesis About Prof. Cynthia L. Sears, MD: Cynthia L. Sears, M.D. is Professor of Medicine, Oncology and Molecular Microbiology and Immunology at the Johns Hopkins University School of Medicine and the Bloomberg School of Public Health. Through her work as an infectious diseases specialist, she studies how bacteria and the microbiome impact gut diseases, particularly human colon cancer. She has long been an active member of the Infectious Diseases Society of America (IDSA), serving as President of IDSA in 2019, is an AAAS Fellow and is currently Editor-in-Chief of The Journal of Infectious Diseases, the flagship journal of the IDSA.

Gut health trends are everywhere, but which ones deserve a closer look, and which ones need a reality check?In this episode, we break down the biggest gut health trends getting clicks, likes, and follows online. From our "hard no" to "I'm curious," we share where each trend lands on our hype scale and explain the science, physiology, and gut-brain connection behind our take.We explore what actually helps symptoms like constipation, bloating, and digestive discomfort without fueling anxiety, wasting money, or creating unnecessary health risks.From viral wellness trends to evidence-based advice, here's what we're discussing:Does the viral chia seed "internal shower" actually cleanse your colon or is that just clever marketing?Are colonics and coffee enemas detox heroes, or do they go against how your gut is designed to work?Can lemon water and apple cider vinegar really "wake up" your digestion first thing in the morning?Can a simple self-care routine improve your gut symptoms, even if it doesn't "heal" your digestive system?Are fermented foods always packed with probiotics or is there more to the story? (Tune in for a revisit of Episode 20!)Can you make colonoscopy prep more tolerable with "prep mocktails" without interfering with the procedure?Can you have too much of a good thing? What happens when "fibermaxxing" goes too far?Are gut-healing protocols and at-home microbiome tests helping you understand your gut or making you more confused and anxious?Do lactose intolerance patches actually work, or does the science tell a different story?Are castor oil packs a legitimate digestive therapy?Whether you're tempted to try the latest gut health hack or just wondering what's worth your attention, this episode will help you separate science from social media. Resources:Chia seeds (Salvia hispanica L.): A therapeutic weapon in metabolic disorders. Food Sci Nutr. 2022 Dec 15;11(1):3-16. doi: 10.1002/fsn3.3035.Guide to Utilization of the Microbiology Laboratory for Diagnosis of Infectious Diseases: 2024 Update by the Infectious Diseases Society of America (IDSA) and the American Society for Microbiology (ASM). Clin Infect Dis. 2024. doi: 10.1093/cid/ciae104.Fermented Foods via ISAPPMisselwitz B, Butter M, Verbeke K, Fox MR. Update on lactose malabsorption and intolerance: pathogenesis, diagnosis and clinical management. Gut. 2019 Nov;68(11):2080-2091. doi: 10.1136/gutjnl-2019-318404. Epub 2019 Aug 19. PMID: 31427404; PMCID: PMC6839734.Learn more about Kate and Dr. Riehl:Website: www.katescarlata.com and www.drriehl.comInstagram: @katescarlata @drriehl and @theguthealthpodcastOrder Kate and Dr. Riehl's book, Mind Your Gut: The Science-Based, Whole-body Guide to Living Well with IBS.  The information included in this podcast is not a substitute for professional medical advice, examination, diagnosis or treatment.  Always seek the advice of your physician or other qualified health care provider before starting any new treatment or making changes to existing treatment.

On episode #98 of the Infectious Disease Puscast, Daniel reviews the infectious disease literature for the weeks of 1/1/26 – 1/14/26. Host: Daniel Griffin Subscribe (free): Apple Podcasts, RSS, email Become a patron of Puscast! Links for this episode Viral Rhinovirus-Associated Lower Respiratory Tract Infection in Hospitalized Adult Patients: A Retrospective Cohort Study (JID) Demise of the Milwaukee Protocol for Rabies (CID) Reply to Willoughby on Demise of the Milwaukee Protocol for Rabies (CID) Bacterial Clinical Practice Guideline by Infectious Diseases Society of America (IDSA): 2025 Guideline on Management and Treatment of Complicated Urinary Tract Infections: Introduction and Methods (CID) Reassessing the 2023 International Society for Cardiovascular Infectious Diseases Duke clinical criteria for infective endocarditis: Impact of excluding fever and updating diagnostic definition (CID) The diagnostic accuracy of procalcitonin for community-acquired bacteremia: an updated systematic review and meta-analysis (CMI: Clincal Microbiology and Infection) Noninferiority of One HPV Vaccine Dose to TwoDoses (NEJM) About the wastewater program (Colorado: Department of Public & Environment) Notes from the Field: Wastewater Surveillance for Measles Virus During a Measles Outbreak — Colorado, August 2025 (CDC: MMWR) Notes from the Field: Retrospective Analysis of Wild-Type Measles Virus in Wastewater During a Measles Outbreak — Oregon, March 24–September 22, 2024 (CDC:MMWR) Fungal The Last of US Season 2 (YouTube) Candidozyma auris (formerly Candida auris): Resistant, long-lasting, and everywhere (CMI: Clincal Microbiology and Infection) Long-range air dispersal as an important source of environmental contamination in Candida auris clustering: possible infection control implication (Infection Control & Hospital Epidemiology) Parasitic Dermlite Dermatoscopes (dermatoscopes.com) Oral ivermectin versus 5% permethrin cream to treat children and adults with classic scabies: multicentre, assessor blinded, cluster randomised clinical trials (BMJ) Music is by Ronald Jenkees Information on this podcast should not be considered as medical advice.

Actinomyces species are considered part of the normal vaginal and urogenital tract flora. The percentage of Pap smears containing Actinomyces-like organisms varies but is most commonly reported as approximately 7% among women using IUDs. That number is supported by multiple sources, including the Infectious Diseases Society of America guideline and several clinical studies. The incidence can be higher or lower depending on the type of IUD; for example, copper IUDs have been associated with rates up to 20%, while levonorgestrel-releasing IUDs show lower rates around 2.9%. In women with an IUD, who are found to have this finding on their liquid-based Pap smear, what is the appropriate management? In this episode, which comes from one of our podcast family members, we will discuss this topic and it's management in both symptomatic and symptomatic (pelvic pain) IUD wearing women. 1. McHugh KE, Sturgis CD, Procop GW, Rhoads DD. The Cytopathology of Actinomyces, Nocardia, and Their Mimickers. Diagnostic Cytopathology. 2017;45(12):1105-1115. doi:10.1002/dc.23816.2. Practice Bulletin No. 186: Long-Acting Reversible Contraception: Implants and Intrauterine Devices. Obstetrics and Gynecology. 2017;130(5):e251-e269. doi:10.1097/AOG.0000000000002400.3. Miller JM, Binnicker MJ, Campbell S, et al. Guide to Utilization of the Microbiology Laboratory for Diagnosis of Infectious Diseases: 2024 Update by the Infectious Diseases Society of America (IDSA) and the American Society for Microbiology (ASM). Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America. 2024; ciae104. doi:10.1093/cid/ciae104.5. Carrara J, Hervy B, Dabi Y, et al. Added-Value of Endometrial Biopsy in the Diagnostic and Therapeutic Strategy for Pelvic Actinomycosis. Journal of Clinical Medicine. 2020;9(3):E821. doi:10.3390/jcm9030821.

Dr. Julie Ann Justo is joined by experts Drs. Krista Gens and Javier A. Villafuerte Gálvez as they dive deep into the gut microbiome and explore the latest therapeutic frontier for C. difficile infections.  From bacteria battles to breakthrough treatments, this one's a must-listen! You can also review the helpful infographic on our website (https://breakpoints-sidp.org/infographics/). This podcast was supported by an unrestricted grant from Nestlé Health Science. References: Helpful review from one of our guest experts: Gens KD, et al. Fecal microbiota transplantation and emerging treatments for Clostridium difficile infection. J Pharm Pract. 2013 Oct;26(5):498-505. doi: 10.1177/0897190013499527. PMID: 23966282. More modern review: Herbin SR, et al. Breaking the Cycle of Recurrent Clostridioides difficile Infections: A Narrative Review Exploring Current and Novel Therapeutic Strategies. J Pharm Pract. 2024 Dec;37(6):1361-1373. doi: 10.1177/08971900241248883. Epub 2024 May 13. PMID: 38739837. Review on designing microbiota based therapies (pre-print only): Ke S, et al. Rational Design of Live Biotherapeutic Products for the Prevention of Clostridioides difficile Infection. 2024 May 02. doi: 10.1101/2024.04.30.591969. [FDA Guidance regarding IND requirements for fecal microbiota transplant](https://www.fda.gov/regulatory-information/search-fda-guidance-documents/enforcement-policy-regarding-investigational-new-drug-requirements-use-fecal-microbiota). 2022 Nov. OpenBiome webpage with resources for hospitals: How to Start an FMT Program. 2025. Peery AF, et al. AGA Clinical Practice Guideline on Fecal Microbiota-Based Therapies for Select Gastrointestinal Diseases. Gastroenterology. 2024 Mar;166(3):409-434. doi: 10.1053/j.gastro.2024.01.008. PMID: 38395525. Johnson S, et al. Clinical Practice Guideline by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA): 2021 Focused Update Guidelines on Management of Clostridioides difficile Infection in Adults. Clin Infect Dis. 2021 Sep 7;73(5):755-757. doi: 10.1093/cid/ciab718. PMID: 34492699. Henry Ford's experience getting fecal microbiota products for patients: Abene S. Fecal Microbiota Capsules Improve CDI Access Through Specialty Pharmacy Integration. Contagion Live. 2025 Jul 11. An international view on CDI management: Mendo-Lopez R, et al. Best Practices in the Management of Clostridioides difficile Infection in Developing Nations. Trop Med Infect Dis. 2024 Aug 19;9(8):185. doi: 10.3390/tropicalmed9080185. PMID: 39195623. Review on investigational LBP agents: Monday L, et al. Microbiota-Based Live Biotherapeutic Products for Clostridioides Difficile Infection- The Devil is in the Details. Infect Drug Resist. 2024 Feb 15;17:623-639. doi: 10.2147/IDR.S419243. PMID: 38375101. More on quorum sensing: Falà AK, et al. Quorum sensing in human gut and food microbiomes: Significance and potential for therapeutic targeting. Front Microbiol. 2022 Nov 25;13:1002185. doi: 10.3389/fmicb.2022.1002185. PMID: 36504831. Economic impacts of CDI pts: Reilly J, et al. Economic impact of multiple recurrent Clostridioides difficile infection in a community teaching hospital. Infect Control Hosp Epidemiol. 2025 Sep 29:1-3. doi: 10.1017/ice.2025.10295. Epub ahead of print. PMID: 41020576.

We are back and live from IDWeek 2025! Drs. Camille Kotton and Roy Chemaly join Febrile to discuss refractory HSV infection in immunocompromised patients!This episode was recorded at an IDWeek 2025 affiliated event in Atlanta, GA on October 20, 2025. Drs. Camille Kotton, Roy Chemaly, and Sara Dong were sponsored speakers by Aicuris Anti-infective Cures AG for this event, however this Febrile content was planned, produced, and reviewed solely by Febrile.Episodes | Consult Notes | Subscribe | Twitter | Merch | febrilepodcast@gmail.comFebrile is produced with support from the Infectious Diseases Society of America (IDSA)

In this episode of Communicable, Erin McCreary and Angela Huttner are joined by Barbara Trautner (St. Louis, USA) and Valéry Lavergne (Vancouver, Canada), the co-chairs and leading authors of the first IDSA guideline on complicated urinary tract infection (cUTI), which was published a few months ago [1]. Together, they discuss the process of developing the guideline from its conception in 2018, the new definition of cUTI, their stepwise approach to clinical decision-making, and some case-by-case scenarios for common antibiotics. They also elaborate on how this guideline compares (and contrasts) to other existing UTI guidelines—including the previous IDSA guideline for UTI [2] —and the clinical need to supply frontline clinicians to identify and distinguish complicated cases from the uncomplicated ones. The episode closes with what essential clinical questions the guests hope to tackle next.  This episode was edited by Kathryn Hostettler and peer reviewed by Maria Ana Flores of Santa Maria Local Health Unit, Lisbon, Portugal.Other resources:European Urologic Association guidelinesUpToDateFDA guidance on complicated UTI ReferencesTrautner BW, et al. Clinical Practice Guideline by Infectious Diseases Society of America (IDSA): 2025 Guideline on Management and Treatment of Complicated Urinary Tract Infections Gupta, K, et al. Clinical Practice Guidelines for the Treatment of Acute Uncomplicated Cystitis and Pyelonephritis in Women: 2010 Update by IDSA

As infecções de pele e partes moles estão entre as mais prevalentes na prática clínica, mas ainda cercadas de confusões conceituais e condutas inconsistentes. Neste episódio, Klinger Soares Faíco Filho recebe as infectologistas Beatriz Soares, Laís Seriacopi e Stefânia Prebianchi para discutir o que realmente importa na abordagem de celulite e erisipela da diferenciação clínica entre os quadros ao manejo racional de antibióticos e à prevenção de recorrências.A conversa percorre desde o reconhecimento das portas de entrada e o controle de comorbidades até o uso criterioso de exames complementares, a definição do tempo de tratamento e os critérios de internação. Um episódio que transforma diretrizes em prática e reforça o papel do julgamento clínico na condução das infecções de pele e partes moles.▶️ Confira o episódio completo e aprimore sua condução diante de um dos temas mais comuns — e desafiadores — da infectologia.Referências do episódioReferência citada aos 06:40STEVENS, D. L. et al. Practice Guidelines for the Diagnosis and Management of Skin and Soft Tissue Infections: 2014 Update by the Infectious Diseases Society of America (IDSA). Clinical Infectious Diseases, v. 59, n. 2, p. e10–e52, 2014. doi:10.1093/cid/ciu296.Referência citada aos 18:20BRASIL. Ministério da Saúde. Consenso Brasileiro de Terapia Antimicrobiana: Infecções de Pele e Partes Moles. Brasília: Ministério da Saúde, 2019. Disponível em: https://www.gov.br/saude/pt-br/assuntos/antimicrobianos.Referência citada aos 22:05ECDC. Antimicrobial resistance surveillance in Europe 2023 – 2021 data. European Centre for Disease Prevention and Control, 2023. Disponível em: https://www.ecdc.europa.eu/en/publications-data/antimicrobial-resistance-surveillance-europe-2023.

The Infectious Diseases Society of America (IDSA) has released new guidelines for the treatment of complicated urinary tract infections. In this episode, we break down the key updates: Changes to the definition of complicated UTIs The role of newer antibiotic agents How and when to use antibiograms A four-step framework for guiding therapy When carbapenems are necessary—and when other options may be just as effective Shorter durations of therapy Join Dr. Barbara Trautner, Dr. Nicolas Cortés-Penfield, and Dr. Kalpana Gupta as they discuss what these guidelines mean for clinicians, microbiologists, and patients.

In this episode of The Association Insights Podcast, we continue our July series on sponsorships, partnerships, and non-dues revenue with a behind-the-scenes look at how one major association is building long-term value through strategic partnerships and innovative fulfillment models.Host Meghan Henning sits down with John Buckley, Senior Director of Business Partnerships and Expo Operations at the Infectious Diseases Society of America (IDSA), to explore how IDWeek has evolved into a flagship experience that delivers for both members and industry partners.With nearly 20 years of experience in nonprofit event strategy, John shares how trust, creativity, and a long-game mindset have transformed IDSA's non-dues revenue approach—from tailored sponsorships to citywide visibility campaigns.

Drs. Anshel Kenkare and Mike Reid share a conversation about the incredible science and current context of lenacapavir for HIV prevention, which was recently approved by the FDA.Episodes | Consult Notes | Subscribe | Twitter | Merch | febrilepodcast@gmail.comFebrile is produced with support from the Infectious Diseases Society of America (IDSA)

This StAR episode features the CID State-of-the-Art Review on Nontuberculous Mycobacterial Pulmonary Disease: Patients, Principles, and Prospects.Our guest stars this episode are:Minh-Vu Nguyen (UC Davis Health)Charles Daley (National Jewish Health, University of Colorado, Icahn School of Medicine at Mt Sinai)Reeti Khare (National Jewish Health)Journal article link: Nguyen MH, Haas MK, Kasperbauer SH, et al. Nontuberculous Mycobacterial Pulmonary Disease: Patients, Principles, and Prospects. Clin Infect Dis. 2024;79(4):e27-e47. doi:10.1093/cid/ciae421Journal companion article - Executive summary link: https://academic.oup.com/cid/article-abstract/79/4/805/7823163From Clinical Infectious DiseasesEpisodes | Consult Notes | Subscribe | Twitter | Merch | febrilepodcast@gmail.comFebrile is produced with support from the Infectious Diseases Society of America (IDSA)

Drs. Till Koch and Annette Hennigs join to discuss their ID podcast Infektiopod and dive into varicella!Check out Infektiopod here!Episodes | Consult Notes | Subscribe | Twitter | Merch | febrilepodcast@gmail.comFebrile is produced with support from the Infectious Diseases Society of America (IDSA)

Drs. Sumanth Cherukumilli, Milagritos Tapia, and Adama Mamby Keita join Febrile to describe an approach to a gray membranous pharyngitis!Episodes | Consult Notes | Subscribe | Twitter | Merch | febrilepodcast@gmail.comFebrile is produced with support from the Infectious Diseases Society of America (IDSA)

Dr. Adam Ratner joins to discuss a case of facial swelling which leads to a conversation about vaccine hesitancy and current outbreaks.Check out Booster Shots: The Urgent Lessons of Measles and the Uncertain Future of Children's Health !Episodes | Consult Notes | Subscribe | Twitter | Merch | febrilepodcast@gmail.comFebrile is produced with support from the Infectious Diseases Society of America (IDSA)

Drs. Morgan Hui, Jonathan Darby, Max Olenski, and Catriona Halliday join Febrile from Australia to share a unique case of a transplant recipient with a painless lump.Episodes | Consult Notes | Subscribe | Twitter | Merch | febrilepodcast@gmail.comFebrile is produced with support from the Infectious Diseases Society of America (IDSA)

Drs. Chelsea Gorsline, Courtney Harris, and Rebecca Kumar join to tell us more about the Transplant ID Early Career Network and how to approach donor call!Episodes | Consult Notes | Subscribe | Twitter | Merch | febrilepodcast@gmail.comFebrile is produced with support from the Infectious Diseases Society of America (IDSA)

This StAR episode features the CID State-of-the-Art Review on Ocular Infections.Our guest stars this episode are:Miriam Barshak (Massachusetts General Hospital; Mass Eye and Ear)Akash Gupta (University of Pittsburgh Medical Center)Journal article link: Barshak MB, Durand ML, Gupta A, Mohareb AM, Dohlman TH, Papaliodis GN. State-of-the-Art Review: Ocular Infections. Clin Infect Dis. 2024;79(5):e48-e64. doi:10.1093/cid/ciae433Journal companion article - Executive summary link: https://academic.oup.com/cid/article-abstract/79/5/1125/7906419From Clinical Infectious DiseasesEpisodes | Consult Notes | Subscribe | Twitter | Merch | febrilepodcast@gmail.comFebrile is produced with support from the Infectious Diseases Society of America (IDSA)

In this episode of the Conscious Design Podcast, Ian Peterman interviews Ravi Sawhney, founder and CEO of RKS Design, a global human-centered design firm. Ravi shares his journey in industrial design, the development of his Psycho-Aesthetics® methodology, and how emotional durability and sustainable materials are shaping the future of innovation in product design.They discuss Ravi's groundbreaking work on electric guitars, including a collaboration with Dave Mason to create the world's first sustainable electric guitar. The conversation dives into circular economy principles and how businesses can successfully integrate aesthetics, function, and sustainability to make a lasting impact.

Drs. Tom Schmidt, George R Thompson, and Nate Bahr solve a pneumonia not responding to antimicrobials and discuss endemic fungal disease!To learn more about the Mycoses Study Group Research and Education Consortium, check out the MSGERC pageEpisodes | Consult Notes | Subscribe | Twitter | Merch | febrilepodcast@gmail.comFebrile is produced with support from the Infectious Diseases Society of America (IDSA)

This StAR episode features the CID State-of-the-Art Review on delusional infestation.Our guest stars this episode are: Alexandra Mendelsohn (Dell Medical School, University of Texas Austin)Alysse Wurcel (Boston Medical Center)Journal article link: https://academic.oup.com/cid/article-abstract/79/2/e1/7718272Journal companion article - Executive summary link: https://academic.oup.com/cid/article-abstract/79/2/287/7718273From Clinical Infectious DiseasesEpisodes | Consult Notes | Subscribe | Twitter | Merch | febrilepodcast@gmail.comFebrile is produced with support from the Infectious Diseases Society of America (IDSA)

In our Season 4 finale wrapping up 2024, Febrile is excited to host our biggest guest list yet to discuss the importance of International Medical Graduates (IMGs) in infectious diseases! Our guests:Ana Del Valle (Pediatric ID faculty at Arkansas Children's Hospital)Cristina Tomatis (Pediatric ID faculty at Nationwide Children's Hospital)Diego Cruz (Current pediatric resident and recent graduate of pediatric ID fellowship program at Nationwide Children's Hospital)Radhika Sheth (Adult ID faculty at Henry Ford Health System)Shweta Anjan (Adult ID faculty at University of Miami and Jackson Memorial Hospital)Zheyi Teoh (Pediatric ID faculty at Seattle Children's Hospital)Cesar Berto (Adult ID faculty at University of Alabama Birmingham)Episodes | Consult Notes | Subscribe | Twitter | Merch | febrilepodcast@gmail.comFebrile is produced with support from the Infectious Diseases Society of America (IDSA)

Drs. Jonathan Ryder and Sarah Turbett discuss blood culture stewardship!Episodes | Consult Notes | Subscribe | Twitter | Merch | febrilepodcast@gmail.comFebrile is produced with support from the Infectious Diseases Society of America (IDSA)

In this episode of HIV unmuted, host Juan Michael Porter II sits down with Jeanne Marrazzo, the Director of the National Institute of Allergy and Infectious Diseases (NIAID), in a conversation that goes beyond the headlines and deep into the heart of HIV research and advocacy. Dr Marrazzo, a leader with decades of experience in infectious disease research, shares her inspiring journey from her roots in Scranton, Pennsylvania, to her groundbreaking work in HIV prevention and care. Through this intimate conversation, listeners will discover what drives Dr. Marrazzo's commitment to equity, diversity and community-centered research, and how her personal and professional experiences shape her vision for the future of HIV science. From the challenges of addressing global health inequities to the optimism surrounding new HIV prevention methods, Dr Marrazzo offers valuable insights into the importance of inclusive messaging, the power of collaboration, and why putting people first remains at the core of her mission. Tune in to hear how Jeanne Marrazzo plans to navigate the evolving landscape of global health as she leads NIAID into a new era, and why she believes that hope, innovation, and community are key to overcoming the ongoing challenges in the HIV response. Meet our guest: Jeanne Marrazzo   Jeanne Marrazzo, MD, MPH, FACP, FIDSA, is the Director of NIAID at the U.S. National Institutes of Health (NIH), where she oversees a USD 6.3 billion budget that supports research to advance understanding, diagnosis and treatment of infectious, immunologic and allergic diseases. She was previously the C. Glenn Cobbs Endowed Chair and Director of Infectious Diseases at the University of Alabama at Birmingham Heersink School of Medicine. She is a Fellow of the American College of Physicians and the Infectious Diseases Society of America (IDSA), and was Treasurer of the IDSA from 2021 to 2023, having served on the board since 2018. She researches the vaginal microbiome, sexually transmitted infections and HIV pre-exposure prophylaxis. She has had leadership roles in the NIH HIV Prevention Trials Network and the Infectious Diseases Clinical Research Consortium. She was a leading voice in communicating science during the COVID-19 pandemic.   Meet our host: Juan Michael Porter II  Juan Michael Porter II is a health journalist, HIV advocate, culture critic, educator and the host of HIV unmuted, the IAS podcast. He is the Senior Editor of TheBody.com and TheBodyPro – and the first person openly living with HIV to hold the position. Juan Michael's reportage combines data dives, personal narratives and policy analyses to address the real-world consequences of ever-shifting legislation on people's health outcomes. He has written for the Public Broadcasting Service, SF Chronicle, Philadelphia Inquirer, Christian Science Monitor, NY Observer, TDF Stages, Playbill, American Theatre, Time Out NY, Queerty, Anti-Racism Daily, Positively Aware, Documentary Magazine, SYFY Wire, Scholastic and Dance Magazine. 

This StAR episode features the CID State-of-the-Art Review on use of antimicrobials at the end of life.Our guest stars this episode are:Daniel Karlin (University of California Los Angeles, UCLA)Christine Pham (UCLA)Daisuke Furukawa (Stanford)Journal article link: Karlin D, Pham C, Furukawa D, et al. State-of-the-Art Review: Use of Antimicrobials at the End of Life. Clin Infect Dis. 2024;78(3):e27-e36. doi:10.1093/cid/ciad735Journal companion article - Executive summary link: https://academic.oup.com/cid/article/78/3/493/7596075From Clinical Infectious DiseasesEpisodes | Consult Notes | Subscribe | Twitter | Merch | febrilepodcast@gmail.comFebrile is produced with support from the Infectious Diseases Society of America (IDSA)

This StAR episode features the CID State-of-the-Art Review on a comprehensive approach to vascular graft infection.Our guest stars this episode are:Hussam TabajaSupavit “Mac” ChesdachaiDaniel DeSimone(from Mayo Clinic, Rochester, Minnesota)Journal article link: Tabaja H, Chesdachai S, Shah AS, et al. Fostering Collaborative Teamwork-A Comprehensive Approach to Vascular Graft Infection Following Arterial Reconstructive Surgery. Clin Infect Dis. 2024;78(6):e69-e80. doi:10.1093/cid/ciae150Journal companion article - Executive summary link: https://academic.oup.com/cid/article/78/6/1391/7651000From Clinical Infectious DiseasesEpisodes | Consult Notes | Subscribe | Twitter | Merch | febrilepodcast@gmail.comFebrile is produced with support from the Infectious Diseases Society of America (IDSA)

Unfortunately, there simply isn't a one-size-fits-all treatment protocol for patients infected with Lyme disease and/or co-infections. This is why it's critical for physicians treating Lyme disease to invest time with patients, thoroughly understand their medical history, and closely monitor symptoms and treatment response. With that in mind, there are currently two different treatment approaches for Lyme disease. The Infectious Disease Society of America (IDSA) and the International Lyme and Associated Diseases Society (ILADS) have each published their own set of evidence-based treatment guidelines. IDSA guidelines recommend a short course of antibiotics, typically 14 to 30 days. IDSA argues that the Borrelia burgdorferi bacteria do not persist in a patient beyond this timeframe and that lingering symptoms are the result of an ongoing immune response and not an active infection. It also cites scientific evidence claiming treatments beyond 30 days are ineffective, unnecessary, and even dangerous. IDSA physicians will stop treatment after 30 days, even if symptoms remain. They advise an additional 30 days of treatment recommended for patients with Lyme arthritis.  On the contrary, ILADS offers its own scientific data to show that a additional treatment with antibiotics is required to eradicate the bacteria. ILADS recognizes that a month of treatment may be sufficient for patients in the acute stage of Lyme disease, but in cases where the spirochete has disseminated and the disease has advanced, a 30-day treatment regimen is inadequate. ILADS guidelines recommend additional antibiotics until a patient's symptoms have been resolved. Treating Lyme disease in its advanced stage can be complicated based on the complexity of the organism itself, differences in each patient's immune system, the length of time infected, and the possible presence of other co-infections transmitted by the same tick. There are several choices in treating Lyme disease, which include oral, intravenous, and intramuscular antibiotic options. Other options may include sequential antibiotic therapy, higher doses of antibiotics, taking antibiotics for a longer period of time, a combination of antibiotics, retreatment, as well as diagnosing and treating co-infections. Some specific antibiotics used in treating Lyme disease are doxycycline, minocycline, amoxicillin, cefuroxime, azithromycin, and clarithromycin. Other tests include measures of blood counts, chemistries, liver function tests, ANA, dsDNA, RF, TSH, free T3, free T4, ESR may be helpful at ruling out other conditions.  Referral to specialist might help to rule out other conditions.  I find shared decision with my patient helpful. I also find follow-up helpful to assess my patient's response to treatment to rule out other conditions. There are additional protocols that may also aid in treating Lyme disease, such as avoiding alcohol, simple and processed sugars, exercising as tolerated, counseling for a Jarisch-Herxheimer reaction, managing symptoms, monitoring and reducing the risk of an adverse event, and reducing stress. However, there is a chance of side effects such as Clostridium difficile-associated diarrhea (CDAD). Probiotic have been prescribed with the hope of reducing the risk of developing CDAD.   

Welcome! Today, we're exploring the key milestones in Lyme disease research and treatment.I had a 57-year-old patient who remained chronically ill after being diagnosed and treated for Lyme disease. He didn't realize that a persistent tick-borne infection could explain his chronic illness. He was treated with a combination of azithromycin and atovaquone for the persistent infection, and today, he is doing well.He was surprised that, despite the milestones in Lyme disease research, he wasn't aware that a persistent infection could lead to his chronic illness. So, let's take a closer look at these milestones.1. 1977: Discovery of Lyme DiseaseOur story begins in 1977 in Lyme, Connecticut. A cluster of children and adults were diagnosed with what was initially thought to be juvenile rheumatoid arthritis. This event marked the identification of Lyme disease as a distinct illness and the start of modern Lyme disease awareness."2. 1982: Discovery of the Bacterium Responsible for Lyme DiseaseIn 1982, Dr. Willy Burgdorfer identified Borrelia burgdorferi, the bacterium responsible for Lyme disease. This discovery was a major milestone, enabling more precise identification and treatment of the disease. 3. 1990: Recognition of Chronic Lyme DiseaseBy 1990, chronic Lyme disease, with its long-term and persistent symptoms, was officially recognized. This led to more comprehensive treatment protocols and increased awareness of the disease's chronic nature.4. 1995: Discovery of Babesia microtiIn 1995, Babesia microti was identified as a co-infection transmitted by the same ticks that carry Lyme disease. This highlighted the complexity of tick-borne illnesses and the need for integrated treatment approaches. 5. 2000: Publication of IDSA and ILADS GuidelinesThe year 2000 saw the publication of treatment guidelines by both the Infectious Disease Society of America (IDSA) and the International Lyme and Associated Diseases Society (ILADS). These guidelines showcased different approaches to treating Lyme disease, marking another significant milestone. 6. Ongoing Research and Future Milestones Research is ongoing, and we look forward to future milestones that could lead to breakthroughs in diagnosis and treatment. Studies on biofilms, persisters, and tick-borne co-infections may enable doctors to develop treatment plans that significantly improve patient outcomes.ConclusionUnderstanding these milestones helps us appreciate the progress made in the fight against Lyme disease. With continued research and dedication, we move closer to effective management and potential cures. Thank you for watching, and stay tuned for more insights on Lyme disease." 

This StAR episode features the CID State-of-the-Art Review on Unintended Consequences: Risk of Opportunistic Infections Associated with Long-term Glucocorticoid Therapies in Adults.Our guest stars this episode are:Daniel Chastain (University of Georgia College of Pharmacy)Megan Spradlin (University of Colorado)Hiba Ahmad (University of Colorado)Andrés F Henao-Martínez (University of Colorado)Journal article link: Chastain DB, Spradlin M, Ahmad H, Henao-Martínez AF. Unintended Consequences: Risk of Opportunistic Infections Associated With Long-term Glucocorticoid Therapies in Adults. Clin Infect Dis. 2024;78(4):e37-e56. doi:10.1093/cid/ciad474Journal companion article - Executive summary link: https://academic.oup.com/cid/article/78/4/811/7643625From Clinical Infectious DiseasesEpisodes | Consult Notes | Subscribe | Twitter | Merch | febrilepodcast@gmail.comFebrile is produced with support from the Infectious Diseases Society of America (IDSA)

This StAR episode features the CID State-of-the-Art Review on ##.Our guest stars this episode are:Arsheena Yassin (Robert Wood Johnson University Hospital)Mariya Huralska (Robert Wood Johnson University Hospital)Journal article link: Yassin A, Huralska M, Pogue JM, Dixit D, Sawyer RG, Kaye KS. State of the Management of Infections Caused by Multidrug-Resistant Gram-Negative Organisms. Clin Infect Dis. 2023;77(9):e46-e56. doi:10.1093/cid/ciad499Journal companion article - Executive summary link: https://academic.oup.com/cid/article/77/9/1223/7408674From Clinical Infectious DiseasesEpisodes | Consult Notes | Subscribe | Twitter | Merch | febrilepodcast@gmail.comFebrile is produced with support from the Infectious Diseases Society of America (IDSA)

Drs. Maxime Billick and Isaac Bogoch from the University of Toronto discuss the buffet of options available for HIV biomedical prevention!Episodes | Consult Notes | Subscribe | Twitter | Merch | febrilepodcast@gmail.comFebrile is produced with support from the Infectious Diseases Society of America (IDSA)

This is episode 33 of the Love, Hope, Lyme podcast. Fred Diamond's popular book, "Love, Hope, Lyme: What Family Members, Partners, and Friends Who Love a Chronic Lyme Survivor Need to Know" offers those who love someone with persistent or chronic Lyme ideas and tips to support this beloved person. It also helps Lyme survivors know how to ask for support. On today's episode, Fred interviews patient-centered healthcare advocate Bruce Alan Fries. It's incredible that Lyme and other tick-borne diseases have political implications. For scores, entities such as the CDC and the Infectious Diseases Society of America (IDSA) refused to acknowledge that chronic Lyme disease even existed and recommended minimal treatment protocols that, in many cases, did not even come close to treating the diseases. Bruce discussed some of the political initiatives he created or participated in to bring more government awareness of these troubling diseases. If someone you love has been afflicted with Lyme disease, watch this podcast now. If you have Lyme disease, listen for ways to get the support you need. The e-version of Fred's book is always free for Lyme survivors. Just reach out to Fred on Facebook or LinkedIn. The print copy can be ordered at https://a.co/d/ifi9Wne.

This StAR episode features the CID State-of-the-Art Review on Staphylococcus aureus bacteremia - controversies in clinical practice.Our guest stars this episode are: Daniel Minter (UCSF)Sarah Doernberg (UCSF)Journal article link: Minter DJ, Appa A, Chambers HF, Doernberg SB. Contemporary Management of Staphylococcus aureus Bacteremia-Controversies in Clinical Practice. Clin Infect Dis. 2023 Nov 30;77(11):e57-e68. doi: 10.1093/cid/ciad500. PMID: 37950887.Journal companion article - Executive summary link: https://academic.oup.com/cid/article/77/11/1489/7453594From Clinical Infectious DiseasesEpisodes | Consult Notes | Subscribe | Twitter | Merch | febrilepodcast@gmail.comFebrile is produced with support from the Infectious Diseases Society of America (IDSA)

Drs. Maria Gabriela Segura, Misti Ellsworth, and Michael Chang from UTHealth Houston McGovern Medical School and Children's Memorial Hermann Hospital chat about an unusual pediatric case of fever of unknown origin.Episodes | Consult Notes | Subscribe | Twitter | Merch | febrilepodcast@gmail.comFebrile is produced with support from the Infectious Diseases Society of America (IDSA)

This StAR episode features the CID State-of-the-Art Review on neurosyphilis.Our guest star this episode is Dr. Matthew Hamill (Johns Hopkins University)Journal article link: Hamill MM, Ghanem KG, Tuddenham S. State-of-the-Art Review: Neurosyphilis. Clin Infect Dis. 2024 May 15;78(5):e57-e68. doi: 10.1093/cid/ciad437. PMID: 37593890.Journal companion article - Executive summary link: https://academic.oup.com/cid/article/78/5/1085/7672813From Clinical Infectious DiseasesEpisodes | Consult Notes | Subscribe | Twitter | Merch | febrilepodcast@gmail.comFebrile is produced with support from the Infectious Diseases Society of America (IDSA)

Happy World Environment Day (June 5 2024)! Our guests celebrate by discussing sustainability in healthcare and infectious diseases. Join Drs. Shreya Doshi, Preeti Jaggi, Pam Lee, and Shira Abeles as they raise awareness about the ways ID professionals can help reduce the negative environmental impact of the way we provide healthcare to our patients!Here is the JPIDS/OFID Supplement Introduction from Drs. Doshi and Jaggi: Healthcare Environmental Sustainability Through an Infectious Diseases LensThe second article mentioned is: Healthcare Sustainability to Address Climate Change, Call for Action to the Infectious Diseases CommunityThe Sustainabil-ID group mentioned in the podcast can be found on Twitter/X @sustain-ID as well as via email at sustainabilityiddocs@gmail.comEpisodes | Consult Notes | Subscribe | Twitter | Merch | febrilepodcast@gmail.comFebrile is produced with support from the Infectious Diseases Society of America (IDSA)

In this episode,  hosts Drs. Temara Hajjat and Peter Lu talk to Dr. Maria Oliva-Hemker about diagnosing and managing Clostridioides difficile (C. diff) in children who have inflammatory bowel disease (IBD). Dr. Oliva-Hemker is the Director of the Division of Pediatric Gastroenterology, Hepatology, and Nutrition and the Stermer Family Professor for Pediatric IBD at the Johns Hopkins University School of Medicine. She is also the Vice Dean for Faculty and the Mary Wallace Stanton Professor for Faculty Affairs. Learning Objectives:Learn how to diagnose Clostridioides difficile, particularly when there is concern about a new IBD diagnosis.Learn how to manage C. diff infection in a patient with known IBD.Learn how to manage recurrent and refractory C. diff infection in a patient with IBD.Link: Clinical Practice Guidelines for Clostridium difficile Infection in Adults and Children: 2017 Update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA)AGA Clinical Practice Guideline on Fecal Microbiota–Based Therapies for Select Gastrointestinal DiseasesACG Clinical Guidelines: Prevention, Diagnosis, and Treatment of Clostridioides difficile InfectionsSupport the Show.This episode is eligible for CME credit! Once you have listened to the episode, click this link to claim your credit. Credit is available to NASPGHAN members (if you are not a member, you should probably sign up). And thank you to the NASPGHAN Professional Education Committee for their review!As always, the discussion, views, and recommendations in this podcast are the sole responsibility of the hosts and guests and are subject to change over time with advances in the field.Check out our merch website!Follow us on Twitter, Facebook and Instagram for all the latest news and upcoming episodes.Click here to support the show.

Step into the role of a hospital epidemiologist managing a measles outbreak response with Drs. Palak Patel, Emily Landon, and David Zhang from the University of Chicago!Episodes | Consult Notes | Subscribe | Twitter | Merch | febrilepodcast@gmail.comFebrile is produced with support from the Infectious Diseases Society of America (IDSA)

This StAR episode features the CID State-of-the-Art Review on acute encephalitis.Our guest stars this episode are: Karen Bloch (Adult ID physician at Vanderbilt University Medical Center)Carol Glaser (Pediatric ID physician at California Department of Public Health)David Gaston (Adult ID physician and clinical microbiologist at Vanderbilt University Medical Center)Arun Venkatesan (Neurologist at Johns Hopkins University)Journal article link: Bloch KC, Glaser C, Gaston D, Venkatesan A. State of the Art: Acute Encephalitis. Clin Infect Dis. 2023;77(5):e14-e33. doi:10.1093/cid/ciad306Journal companion article - Executive summary link: https://academic.oup.com/cid/article/77/5/669/7269079From Clinical Infectious DiseasesEpisodes | Consult Notes | Subscribe | Twitter | Merch | febrilepodcast@gmail.comFebrile is produced with support from the Infectious Diseases Society of America (IDSA)

This StAR episode features the CID State-of-the-Art Review on periprosthetic joint infections.Our guest stars this episode are: Sandra Nelson (ID physician at Massachusetts General Hospital)Jodian Pinkney (ID physician at Massachusetts General Hospital)Antonia Chen (Orthopedic surgeon at Brigham and Women's Hospital)Aaron Tande (ID physician at Mayo Clinic)Journal article link: Nelson SB, Pinkney JA, Chen AF, Tande AJ. Periprosthetic Joint Infection: Current Clinical Challenges. Clin Infect Dis. 2023;77(7):e34-e45. doi:10.1093/cid/ciad360Journal companion article - Executive summary link: https://academic.oup.com/cid/article/77/7/939/7289507From Clinical Infectious DiseasesEpisodes | Consult Notes | Subscribe | Twitter | Merch | febrilepodcast@gmail.comFebrile is produced with support from the Infectious Diseases Society of America (IDSA)

This StAR episode features the CID State-of-the-Art Review: Frame Shift – Focusing on Harm Reduction and Shared Decision Making for People Who Use Drugs Hospitalized with Infections.Our guest stars this episode are: Dr. Kinna Thakarar (ID and Addiction Medicine physician at MaineHealth/Tufts University School of Medicine)Dr. Ayesha Appa (ID and Addiction Medicine physician at University of California San Francisco, UCSF)Chastity Tuell (Harm reductionist and Washington County Program Director for Maine Access Points)Journal article link: Thakarar K, Appa A, Abdul Mutakabbir JC, Goff A, Brown J 3rd, Tuell C, Fairfield K, Wurcel A. Frame Shift: Focusing on Harm Reduction and Shared Decision Making for People Who Use Drugs Hospitalized With Infections. Clin Infect Dis. 2024 Feb 17;78(2):e12-e26. doi: 10.1093/cid/ciad664. PMID: 38018174.Journal companion article - Executive summary link: https://academic.oup.com/cid/article/78/2/233/7453720From Clinical Infectious DiseasesEpisodes | Consult Notes | Subscribe | Twitter | Merch | febrilepodcast@gmail.comFebrile is produced with support from the Infectious Diseases Society of America (IDSA)

This StAR episode features the CID State-of-the-Art Review on evaluation and management of diabetes-related foot infections.Our guest stars this episode are:Dr. Meghan Brennan (ID physician at University of Wisconsin)Dr. Marcos Schechter (ID physician at Emory University)Dr. Tze-Woei Tan (Vascular surgeon at University of Southern California)Dr. David Armstrong (Podiatric surgeon at University of Southern California)Journal article link: Nicolas W Cortes-Penfield, David G Armstrong, Meghan B Brennan, Maya Fayfman, Jonathan H Ryder, Tze-Woei Tan, Marcos C Schechter, Evaluation and Management of Diabetes-related Foot Infections, Clinical Infectious Diseases, Volume 77, Issue 3, 1 August 2023, Pages e1–e13, https://doi.org/10.1093/cid/ciad255Journal companion article - Executive summary link: https://academic.oup.com/cid/article/77/3/335/7242512From Clinical Infectious DiseasesEpisodes | Consult Notes | Subscribe | Twitter | Merch | febrilepodcast@gmail.comFebrile is produced with support from the Infectious Diseases Society of America (IDSA)

Drs. Paul Sax, Tara Vijayan, and Allan Tunkel join Febrile to chat about the debut of a new series called “StAR”!! These upcoming episodes will highlight the outstanding Clinical Infectious Diseases (CID) journal State-of-the-Art Reviews (StAR), which cover common clinical topics that ID clinicians encounter. Learn more about the creation of these articles from these CID editors before we kick off 4 back-to-back episodes!!Episodes | Consult Notes | Subscribe | Twitter | Merch | febrilepodcast@gmail.comFebrile is produced with support from the Infectious Diseases Society of America (IDSA)

Drs. Jack Flores and Madan Kumar chat about the nuances of Kawasaki disease (and provide a mystery riddle!! solution in the Consult Notes!)Episodes | Consult Notes | Subscribe | Twitter | Merch | febrilepodcast@gmail.comFebrile is produced with support from the Infectious Diseases Society of America (IDSA)

Drs. Sumanth Cherukumilli, Emma Mohr, and Paul Spearman join for a live Febrile recording at the St. Jude / PIDS Pediatric Infectious Diseases Research Conference in Memphis, TN. They cover some learning points about early onset neonatal sepsis and chat about career development. Thank you to the conference organizers for the opportunity!Episodes | Consult Notes | Subscribe | Twitter | Merch | febrilepodcast@gmail.comFebrile is produced with support from the Infectious Diseases Society of America (IDSA)

Drs. Genevieve Martin, Catherine Marshall, and Bart Currie from the Royal Darwin Hospital share their approach to Burkholderia pseudomallei aka melioidosis!Episodes | Consult Notes | Subscribe | Twitter | Merch | febrilepodcast@gmail.comFebrile is produced with support from the Infectious Diseases Society of America (IDSA). Audio editing/mixing provided by Bentley Brown.

Drs. Michael Moran and Swapnil Lanjewar from the University of Wisconsin-Madison walk through a case and their approach to the common ID consult for fever and rash.Episodes | Consult Notes | Subscribe | Twitter | Merch | febrilepodcast@gmail.comFebrile is produced with support from the Infectious Diseases Society of America (IDSA). Audio editing/mixing by Bentley Brown.

Future physician Sophie Samson, Dr. Kristen Bastug, and Dr. Beth Thielen discuss a case of a 7 year old girl who presented with new onset seizure, headache, and fever in Minnesota.Episodes | Consult Notes | Subscribe | Twitter | Merch | febrilepodcast@gmail.comFebrile is produced with support from the Infectious Diseases Society of America (IDSA)

• Background of Dr. John Lambert: Dr. John Lambert was born in Scotland, parents immigrated to America, thus obtaining an American education. Returned to the UK in 1999 before settling in Dublin, Ireland shortly after. Working as an infectious disease and Lyme specialist for 18 years. • Education & Professional Journey: College in Kalamazoo, Michigan. Attended University of Sterling in Scotland. Expressed the challenges of transitioning between countries. Always had an inclination towards medical school, initially interested in tropical medicine. Work experience in Haiti at a Mission Hospital. • Infectious Disease Conferences & Updates: Attended a recent Infectious Disease Society of America (IDSA) conference in Boston. Updates on Lyme, coronavirus, HIV/AIDS, tropical medicine, and vaccine developments. • Intricacies of Infectious Diseases: The dual excitement of diagnosing and treating infectious diseases, like Lyme disease. The significance of monitoring patients. Emphasis on evidence-based treatments and results. • Publications and Expertise: Dr. Lambert's 25+ publications. The importance of verifying experts through PubMed searches. The challenges of diagnostics in the Lyme community. • Defining Lyme Disease: Tick Boot Camp provides Tick Boot Camp's definition of Lyme disease. Dr. Lambert's perspective on the definition and the polymicrobial nature of Lyme. • Treatment Guidelines and Controversies: Irish guidelines on Lyme treatment. The debate on chronic Lyme and the skepticism surrounding it. • Immune System Implications: Lyme disease's dual impact on the immune system: immune suppression and potential autoimmune reactions. Discussion on the potential similarities and differences between Lyme disease and other conditions like long COVID. • Diagnostic Tools and Collaborations: Collaboration with Dr. Samiy from the University of North Carolina State. Newer diagnostic tools and their significance. • Treatment Modalities and Approaches: The utilization of LDN (Low Dose Naltrexone) and NAC (N-acetyl cysteine). The importance of maintaining a healthy microbiome. Dr. Lambert's collaborative approach, working alongside herbalists. • Final Thoughts: Emphasizing the bacterial nature of Lyme disease. The importance of timely diagnosis and appropriate treatment.

On this episode, we review the 2023 Hepatitis C Guidance that was recently published by the Infectious Diseases Society of America (IDSA) and the American Association for the Study of Liver Diseases (AASLD). We discuss the pre-treatment work-up, various treatment options, and drug-drug interactions/clinical pearls for the most commonly used direct-acting antivirals.  Cole and I are happy to share that our listeners can claim ACPE-accredited continuing education for listening to this podcast episode! We have continued to partner with freeCE.com to provide listeners with the opportunity to claim 1-hour of continuing education credit for select episodes. For existing Unlimited (Gold) freeCE members, this CE option is included in your membership benefits at no additional cost! A password, which will be given at some point during this episode, is required to access the post-activity test. To earn credit for this episode, visit the following link below to go to freeCE's website: https://www.freece.com/ If you're not currently a freeCE member, we definitely suggest you explore all the benefits of their Unlimited Membership on their website and earn CE for listening to this podcast. Thanks for listening! We want to give a big thanks to our sponsor, High-Powered Medicine. HPM is a book/website database of summaries for over 150 landmark clinical trials. You can get a copy of HPM, written by Dr. Alex Poppen, PharmD, at the links below:  Purchase a subscription or PDF copy - https://highpoweredmedicine.com/ Purchase the paperback and hardcover - Barnes and Noble website We want to give a big thanks to our main sponsor Pyrls. Try out their drug information app today. Visit the website below for a free trial: www.pyrls.com/corconsultrx If you want to support the podcast, check out our Patreon account. Subscribers will have access to all previous and new pharmacotherapy lectures as well as downloadable PowerPoint slides for each lecture. You can find our account at the website below:  www.patreon.com/corconsultrx If you have any questions for Cole or me, reach out to us on any of the following: Text - 415-943-6116 Mike - mcorvino@corconsultrx.com Cole - cswanson@corconsultrx.com Instagram and other social media platforms - @corconsultrx  This podcast reviews current evidence-based medicine and pharmacy treatment options. This podcast is intended to be used for educational purposes only and is intended for healthcare professionals and students. This podcast is not for patients and not intended as advice or treatment.